Prot# VX11-950-116: An Open-Label, Phase 4 study of Telaprevir, Peginterferon Alfa-2a(Pegasys), and Ribavirin(Copegus) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not

Project: Research project

Project Details

StatusFinished
Effective start/end date3/8/12 → 3/8/16

Funding

  • Parexel (VX11-950-116 // VX11-950-116)
  • Vertex Pharmaceuticals Incorporated (VX11-950-116 // VX11-950-116)